New Atlas23h
RNA therapy an effective alternative to lifelong, painful eye injections
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
Stem cells can tailor their role in gene therapy based on the underlying disease, study suggests
RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...
University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first
Its lead gene therapy candidate has the potential to be faster, less expensive, and more widely available than current CAR T ...
BioSpace4d
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
GEN3d
Navigating Quality Control and Release Testing in Cell and Gene Therapy Development
In this GEN webinar, our speakers will present important considerations for quality control testing for biosafety and product ...
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...
BioPharma Dive4d
Sickle cell patient dies in Beam study of base editing therapy
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
BioWorld10d
BioFuture 2024: FDA eases the way for cell and gene therapy companies
Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is ...
Baylor College of Medicine4d
Grants awarded to leading investigators at Baylor's Center for Cell and Gene Therapy
Three investigators at Baylor College of Medicine’s (BCM) Center for Cell and Gene Therapy Institute (CAGT) have been awarded G-Rex Grants totaling $475,000 by ScaleReady, in collaboration with Wilson ...
Q&A: How a 'switchable' CAR-T therapy sets its sights on deadly brain cancer
UC San Francisco treated its first brain cancer patient with an experimental new CAR-T therapy discovered and manufactured at ...